elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q58407688-6CDE294A-8810-4C3C-95FC-324FF2C3920C
Q58407688-6CDE294A-8810-4C3C-95FC-324FF2C3920C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q58407688-6CDE294A-8810-4C3C-95FC-324FF2C3920C
Anti-LAG-3 or Urelumab Alone and in Combination With Nivolumab in Treating Patients With Recurrent Glioblastoma
P31
Q58407688-6CDE294A-8810-4C3C-95FC-324FF2C3920C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q58407688-6CDE294A-8810-4C3C-95FC-324FF2C3920C
rank
NormalRank
type
BestRank
Statement
P31
clinical trial